Bio-Path Holdings, Inc.: Bio-Path Holdings Provides 2025 Clinical and Operational Update
Advancing Multiple Programs in Areas of Significant Unmet Medical Need Several Milestones Across Clinical Development Pipeline Expected in 2025 HOUSTON, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Bio-Path Hold ...
LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers
CD123 Gammabody®First-in-human study enrolling adult patients with CD123-expressing AML or MDSInitial Phase 1 data read-out ...
PureTech announces receipt of FDA Fast Track Designation for LYT-200 in AML
PureTech Health (PRTC) announced that the U.S. Food and Drug Administration has granted Fast Track designation to LYT-200, a ...
Aptose Biosciences, Inc.: Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial
Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company, today announced dosing ...
PharmiWeb3h
PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today ...
Hosted on MSN3h
How Is Leukemia Diagnosed?
Medically reviewed by Doru Paul, MD Leukemia is a cancer of the blood-forming tissues that often develops in the bone marrow.
Cullinan Therapeutics' CLN-978 And Zipalertinib Look Promising In NSCLC
Cullinan offers promising oncology and autoimmune products, strong financials, and potential for growth, making it a ...
Aptose Biosciences Initiates TUSCANY Trial for Frontline AML Therapy
Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...
Aptose announces first AML patients dosed in TUSCANY trial
Aptose Biosciences (APTO) announced dosing the first set of patients in the TUSCANY Phase 1/2 study with tuspetinib in combination with ...